Cost-effective antimicrobial strategies US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Cost-effective antimicrobial strategies. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Cost-effective antimicrobial strategies US Medical PG Question 1: A 64-year-old woman with a past medical history of poorly managed diabetes presents to the emergency department with nausea and vomiting. Her symptoms started yesterday and have been progressively worsening. She is unable to eat given her symptoms. Her temperature is 102°F (38.9°C), blood pressure is 115/68 mmHg, pulse is 120/min, respirations are 17/min, and oxygen saturation is 98% on room air. Physical exam is notable for left-sided costovertebral angle tenderness, and urinalysis demonstrates bacteriuria and pyuria. The patient is admitted to the hospital and started on IV ceftriaxone. On day 3 of her hospital stay she is afebrile, able to eat and drink, and feels better. Which of the following antibiotic regimens should be started or continued as an outpatient upon discharge?
- A. Amoxicillin
- B. Nitrofurantoin
- C. Ciprofloxacin
- D. Ceftriaxone
- E. Trimethoprim-sulfamethoxazole (Correct Answer)
Cost-effective antimicrobial strategies Explanation: ***Trimethoprim-sulfamethoxazole***
- This patient presents with **acute pyelonephritis**, indicated by fever, CVA tenderness, bacteriuria, and pyuria, requiring a 7-14 day course of treatment.
- After 3 days of IV ceftriaxone with clinical improvement, **step-down to oral therapy** is appropriate.
- **Trimethoprim-sulfamethoxazole** is a first-line oral agent for completing treatment of uncomplicated pyelonephritis and is preferred when **local resistance rates are <20%** and no specific resistance data is available.
- It achieves adequate concentrations in renal tissue and is cost-effective for outpatient therapy.
*Amoxicillin*
- **Amoxicillin** is not recommended for pyelonephritis due to **high resistance rates** among common uropathogens like *E. coli* (often >30%).
- It does not achieve adequate concentrations in the renal parenchyma to effectively treat **upper urinary tract infections**.
*Nitrofurantoin*
- **Nitrofurantoin** is concentrated in the bladder and is highly effective for **lower urinary tract infections (cystitis)**.
- It is **contraindicated for pyelonephritis** because it does not reach therapeutic levels in the renal parenchyma or bloodstream.
- Additionally, it should be avoided in patients with impaired renal function.
*Ciprofloxacin*
- **Ciprofloxacin** is also a first-line oral agent for pyelonephritis and would be an appropriate choice for step-down therapy.
- However, when no culture or susceptibility data is available, **TMP-SMX is generally preferred** as an initial oral choice due to concerns about promoting fluoroquinolone resistance and potential adverse effects (tendonitis, QT prolongation, C. difficile).
- Fluoroquinolones are particularly valuable when reserved for cases with known resistance to other agents or specific patient contraindications.
*Ceftriaxone*
- **Ceftriaxone** is an IV third-generation cephalosporin used for initial empiric treatment of acute pyelonephritis in hospitalized patients.
- Once the patient is **clinically stable, afebrile, and tolerating oral intake**, transitioning to oral therapy is standard practice.
- Continued IV therapy as an outpatient is unnecessarily invasive and costly when oral options are effective.
Cost-effective antimicrobial strategies US Medical PG Question 2: A 72-year-old man is admitted to the hospital with productive cough and fever. A chest radiograph is obtained and shows lobar consolidation. The patient is diagnosed with pneumonia. He has a history of penicillin allergy. The attending physician orders IV levofloxacin as empiric therapy. On morning rounds the next day, the team discovers that the patient was administered ceftriaxone instead of levofloxacin. The patient has already received a full dose of ceftriaxone and had no signs of allergic reaction, and his pneumonia appears to be improving clinically. What is the most appropriate next step?
- A. Administer diphenhydramine as prophylaxis against allergic reaction
- B. Continue with ceftriaxone as empiric therapy
- C. Switch the patient to oral azithromycin in preparation for discharge and home therapy
- D. Switch the patient back to levofloxacin and discuss the error with the patient
- E. Continue with ceftriaxone and add azithromycin as inpatient empiric pneumonia therapy (Correct Answer)
Cost-effective antimicrobial strategies Explanation: ***Continue with ceftriaxone and add azithromycin as inpatient empiric pneumonia therapy***
- This is the **guideline-recommended approach** for hospitalized community-acquired pneumonia (CAP) according to ATS/IDSA guidelines.
- Ceftriaxone (beta-lactam) plus azithromycin (macrolide) provides **dual coverage** for typical bacteria (Streptococcus pneumoniae) and atypical organisms (Mycoplasma, Chlamydophila, Legionella).
- Since the patient has already tolerated ceftriaxone without allergic reaction despite penicillin allergy history, continuing it is safe, and **adding azithromycin completes appropriate empiric therapy** for a 72-year-old hospitalized patient.
- The cross-reactivity between penicillins and cephalosporins is low (1-3%), and the patient's tolerance of ceftriaxone confirms safety.
*Continue with ceftriaxone as empiric therapy*
- While the patient is improving on ceftriaxone and tolerated it without allergic reaction, **monotherapy with a beta-lactam alone is suboptimal** for hospitalized CAP.
- Guidelines recommend dual therapy (beta-lactam + macrolide) or fluoroquinolone monotherapy for hospitalized non-ICU patients to ensure adequate atypical coverage.
- Continuing ceftriaxone alone misses potential atypical pathogens that may be contributing to the pneumonia.
*Switch the patient to oral azithromycin in preparation for discharge and home therapy*
- It is **premature to switch to oral therapy** or consider discharge after only one day of treatment for a 72-year-old with pneumonia requiring hospitalization.
- The patient should remain on IV therapy until clinically stable (afebrile, hemodynamically stable, improving oxygenation) for an appropriate duration.
*Administer diphenhydramine as prophylaxis against allergic reaction*
- Since the patient has already tolerated a full dose of ceftriaxone without any allergic reaction, **prophylactic antihistamines are unnecessary**.
- The low cross-reactivity between penicillins and third-generation cephalosporins, combined with the successful first dose, indicates minimal risk.
*Switch the patient back to levofloxacin and discuss the error with the patient*
- Switching back to levofloxacin is **unnecessary and potentially disruptive** given that the patient is clinically improving on ceftriaxone and has demonstrated tolerance to it.
- While the original plan was levofloxacin (appropriate fluoroquinolone monotherapy), the inadvertent use of ceftriaxone has proven safe and provides an opportunity to implement the preferred dual-therapy regimen.
- While discussing medication errors is important for transparency, the immediate medical priority is optimizing pneumonia treatment.
Cost-effective antimicrobial strategies US Medical PG Question 3: A 77-year-old woman is brought to the emergency department from her nursing home because she was found down overnight. On presentation she was found to be delirious and was unable to answer questions. Chart review shows that she is allergic to cephalosporins. Her temperature is 102.2°F (39°C), blood pressure is 105/52 mmHg, pulse is 94/min, and respirations are 23/min. Physical exam reveals a productive cough. A metabolic panel is obtained with the following results:
Serum:
Na+: 135 mEq/L
Cl-: 95 mEq/L
K+: 4 mEq/L
HCO3-: 19 mEq/L
BUN: 40 mg/dL
Creatinine: 2.5 mg/dL
Glucose: 150 mg/dL
Based on these findings two different drugs are started empirically. Gram stain on a blood sample is performed showing the presence of gram-positive organisms on all samples. One of the drugs is subsequently stopped. The drug that was most likely stopped has which of the following characteristics?
- A. Resistance conveyed through acetylation
- B. Associated with red man syndrome
- C. Single-ringed ß-lactam structure (Correct Answer)
- D. Causes discolored teeth in children
- E. Accumulates inside bacteria via O2-dependent uptake
Cost-effective antimicrobial strategies Explanation: ***Single-ringed ß-lactam structure***
- The patient presents with **sepsis** due to **pneumonia** likely caused by **gram-positive organisms**. Given a cephalosporin allergy, **aztreonam** (a monobactam) would be an initial empirical antibiotic choice to cover gram-negative bacteria, alongside a drug for gram-positive coverage (like vancomycin).
- Since the **blood cultures** confirmed **gram-positive organisms**, the drug covering gram-negative bacteria (aztreonam) would be stopped. Aztreonam is characterized by its **single-ringed β-lactam structure**.
*Resistance conveyed through acetylation*
- This mechanism of resistance is typical of **aminoglycosides** (e.g., gentamicin) and **chloramphenicol**.
- Aminoglycosides were unlikely to be one of the empirically started drugs, as they are often used in combination with β-lactams, and this patient has a cephalosporin allergy.
*Associated with red man syndrome*
- **Red man syndrome** is a common adverse effect associated with **vancomycin** administration, especially with rapid infusion.
- Vancomycin would likely be continued, as it effectively targets gram-positive organisms, including **MRSA**, and is a suitable alternative given the cephalosporin allergy.
*Causes discolored teeth in children*
- This is a characteristic side effect of **tetracyclines** (e.g., doxycycline), which are contraindicated in young children and pregnant women due to their effects on bone and teeth development.
- Tetracyclines are not typically first-line empiric therapy for severe pneumonia or sepsis, especially in an elderly patient.
*Accumulates inside bacteria via O2-dependent uptake*
- This describes the mechanism of uptake for **aminoglycosides**. Their entry into bacteria is an **energy-dependent process** requiring oxygen.
- As mentioned, aminoglycosides are less likely to be the initial drug stopped in this scenario, as they target gram-negative bacteria.
Cost-effective antimicrobial strategies US Medical PG Question 4: A 15-year-old boy presents with his father to the urgent care department with a 5-day history of frequent diarrhea, occasionally mixed with streaks of blood. Stool cultures are pending, but preliminary stool samples demonstrate fecal leukocytes and erythrocytes. The patient's vital signs are within normal limits, and he is started on outpatient therapy for presumed Shigella infection. Which of the following was the young man most likely started on?
- A. Oral vancomycin
- B. Oral erythromycin
- C. Oral metronidazole
- D. An oral quinolone
- E. Oral trimethoprim-sulfamethoxazole (TMP-SMX) (Correct Answer)
Cost-effective antimicrobial strategies Explanation: **Oral trimethoprim-sulfamethoxazole (TMP-SMX)**
- **TMP-SMX** is a traditional first-line treatment for **Shigella infection** in settings where susceptibility is expected or confirmed.
- The patient's presentation with **bloody diarrhea**, **fecal leukocytes**, and **erythrocytes** is classic for **Shigella dysentery**.
- While **resistance rates vary by region**, TMP-SMX remains an appropriate choice when local susceptibility patterns support its use.
- It is cost-effective, well-tolerated, and appropriate for outpatient management of uncomplicated cases.
*Oral vancomycin*
- Vancomycin is specifically used for **Clostridioides difficile infection** and does not treat Shigella.
- It has **poor oral absorption** and no activity against Gram-negative enteric pathogens like Shigella.
*Oral erythromycin*
- Erythromycin is primarily effective against **Campylobacter jejuni** and respiratory pathogens.
- It has **limited activity against Shigella** and resistance rates are high, making it an inappropriate choice.
*Oral metronidazole*
- Metronidazole treats **anaerobic bacteria** and protozoal infections (*Giardia*, *Entamoeba histolytica*).
- It has **no significant activity against Shigella**, a facultative anaerobic Gram-negative bacillus.
*An oral quinolone*
- **Fluoroquinolones** (e.g., ciprofloxacin) are highly effective against Shigella and often used as first-line therapy, particularly in areas with high TMP-SMX resistance.
- They are increasingly preferred in current guidelines due to rising resistance to TMP-SMX.
- However, in the context of empiric outpatient treatment where susceptibility is presumed, **TMP-SMX** may still be chosen initially as a narrower-spectrum, cost-effective option, with fluoroquinolones reserved based on culture results or treatment failure.
Cost-effective antimicrobial strategies US Medical PG Question 5: A 38-year-old female presents to the emergency room with fevers, fatigue, and anorexia for over a month. Past medical history includes mild mitral valve prolapse. She underwent an uncomplicated tooth extraction approximately 6 weeks ago. Her vital signs include a temperature of 100.8 F, pulse of 83, blood pressure of 110/77, and SpO2 of 97% on room air. On exam, you note a grade III/VI holosystolic murmur at the apex radiating to the axilla as well as several red, painful nodules on her fingers. Which of the following is the next best course of action?
- A. Blood cultures are not needed. Start empiric antibiotics
- B. Start anticoagulation with heparin
- C. Consult cardiothoracic surgery for mitral valve replacement
- D. Obtain blood cultures x3 sites over 24 hours and start antibiotics after culture results are available
- E. Obtain blood cultures x3 sites over 1 hour and start empiric antibiotics (Correct Answer)
Cost-effective antimicrobial strategies Explanation: ***Obtain blood cultures x3 sites over 1 hour and start empiric antibiotics***
- The patient's presentation with **fever, fatigue, anorexia, new murmur, and painful finger nodules (Osler's nodes)** after a recent dental procedure strongly suggests **infective endocarditis**. Prompt initiation of **empiric antibiotics** after obtaining adequate blood cultures is crucial to improve outcomes and prevent further complications like septic emboli or valvular damage.
- Obtaining **multiple blood cultures rapidly (e.g., three sets over 1 hour)** from different sites maximizes the chance of isolating the causative organism before antibiotics are given, enabling targeted therapy later, while minimizing delay to treatment.
*Blood cultures are not needed. Start empiric antibiotics*
- **Blood cultures are essential** for diagnosing infective endocarditis, identifying the causative organism, and guiding appropriate antibiotic therapy. Skipping blood cultures could lead to inappropriate antibiotic selection and treatment failure.
- While empiric antibiotics are warranted, they should always be initiated **after blood cultures** have been drawn to avoid sterilizing the blood and making microbial identification difficult.
*Start anticoagulation with heparin*
- **Anticoagulation is generally contraindicated** in infective endocarditis due to the increased risk of hemorrhagic complications, especially in cases of septic emboli to the brain.
- While patients with endocarditis can form vegetations that may embolize, the risks of **bleeding outweigh the benefits** of routine anticoagulation.
*Consult cardiothoracic surgery for mitral valve replacement*
- While **mitral valve prolapse** is a risk factor for endocarditis and severe valvular damage may eventually require surgery, primary management involves **antibiotic therapy**.
- Surgical intervention is typically reserved for cases with **severe valvular regurgitation/stenosis leading to heart failure**, uncontrolled infection despite antibiotics, or recurrent emboli, and is not the immediate next step.
*Obtain blood cultures x3 sites over 24 hours and start antibiotics after culture results are available*
- Waiting for **24 hours to collect blood cultures** would significantly delay the initiation of antibiotics, which is dangerous in a potentially life-threatening infection like endocarditis.
- Delaying antibiotics until **culture results are available** could take several days, leading to worsening infection, organ damage, and increased mortality. **Empiric antibiotics** must be started promptly after initial blood collection.
Cost-effective antimicrobial strategies US Medical PG Question 6: In a randomized controlled trial studying a new treatment, the primary endpoint (mortality) occurred in 14.4% of the treatment group and 16.7% of the control group. Which of the following represents the number of patients needed to treat to save one life, based on the primary endpoint?
- A. 1/(0.144 - 0.167)
- B. 1/(0.167 - 0.144) (Correct Answer)
- C. 1/(0.300 - 0.267)
- D. 1/(0.267 - 0.300)
- E. 1/(0.136 - 0.118)
Cost-effective antimicrobial strategies Explanation: ***1/(0.167 - 0.144)***
- The **Number Needed to Treat (NNT)** is calculated as **1 / Absolute Risk Reduction (ARR)**.
- The **Absolute Risk Reduction (ARR)** is the difference between the event rate in the control group (16.7%) and the event rate in the treatment group (14.4%), which is **0.167 - 0.144**.
*1/(0.144 - 0.167)*
- This calculation represents 1 divided by the **Absolute Risk Increase**, which would be relevant if the treatment increased mortality.
- The **NNT should always be a positive value**, indicating the number of patients to treat to prevent one adverse event.
*1/(0.300 - 0.267)*
- This option uses arbitrary numbers (0.300 and 0.267) that do not correspond to the given **mortality rates** in the problem.
- It does not reflect the correct calculation for **absolute risk reduction** based on the provided data.
*1/(0.267 - 0.300)*
- This option also uses arbitrary numbers not derived from the problem's data, and it would result in a **negative value** for the denominator.
- The difference between event rates of 0.267 and 0.300 is not present in the given information for this study.
*1/(0.136 - 0.118)*
- This calculation uses arbitrary numbers (0.136 and 0.118) that are not consistent with the reported **mortality rates** of 14.4% and 16.7%.
- These values do not represent the **Absolute Risk Reduction** required for calculating NNT in this specific scenario.
Cost-effective antimicrobial strategies US Medical PG Question 7: A 26-year-old patient presents to your office with rhinorrhea that you believe to be viral in origin. He respectfully requests treatment with antibiotics, and he demonstrates an understanding of the risks, benefits, and alternatives to treatment. His mental status is intact, and you believe him to have full decision-making capacity. Which of the following is the best course of action?
- A. Refer the patient to an infectious disease specialist
- B. Prescribe ciprofloxacin
- C. Prescribe amoxicillin
- D. Deny the patient's request (Correct Answer)
- E. Prescribe zidovudine
Cost-effective antimicrobial strategies Explanation: ***Deny the patient's request***
- As a physician, you have a professional obligation to act in the patient's best interest, which includes avoiding **unnecessary treatments** that could cause harm.
- Prescribing antibiotics for a **viral infection** contributes to **antibiotic resistance**, exposes the patient to potential side effects (e.g., *C. difficile* infection), and contradicts evidence-based medical practice.
*Refer the patient to an infectious disease specialist*
- This is an **unnecessary referral** as the diagnosis is clear (viral rhinorrhea) and does not require specialized infectious disease management.
- Referral would incur **additional healthcare costs** and delays for a condition that does not warrant such specialized consultation.
*Prescribe ciprofloxacin*
- Ciprofloxacin is a **broad-spectrum antibiotic** that is completely ineffective against viral infections and carries a risk of significant side effects, including **tendon rupture** and *C. difficile* infection.
- Misuse of powerful antibiotics like ciprofloxacin promotes **antibiotic resistance**, making future bacterial infections harder to treat.
*Prescribe amoxicillin*
- Amoxicillin is an antibiotic and, like other antibiotics, is **ineffective against viral infections** such as viral rhinorrhea.
- Prescribing it would contribute to **antibiotic resistance** and expose the patient to potential drug side effects (e.g., rash, gastrointestinal upset) without any clinical benefit.
*Prescribe zidovudine*
- Zidovudine is an **antiretroviral medication** specifically used for the treatment of **HIV infection**.
- It has absolutely **no role** in treating common viral rhinorrhea and would be an inappropriate and potentially harmful prescription.
Cost-effective antimicrobial strategies US Medical PG Question 8: An investigator is studying the genetic profile of an isolated pathogen that proliferates within macrophages. The pathogen contains sulfatide on the surface of its cell wall to prevent fusion of the phagosome and lysosome. She finds that some of the organisms under investigation have mutations in a gene that encodes the enzyme required for synthesis of RNA from a DNA template. The mutations are most likely to reduce the therapeutic effect of which of the following drugs?
- A. Pyrazinamide
- B. Ethambutol
- C. Rifampin (Correct Answer)
- D. Streptomycin
- E. Levofloxacin
Cost-effective antimicrobial strategies Explanation: ***Rifampin***
- **Rifampin** specifically targets bacterial **DNA-dependent RNA polymerase**, inhibiting **RNA synthesis**. Mutations in the gene encoding this enzyme would directly reduce rifampin's binding and effectiveness.
- The description of the pathogen thriving within macrophages and using **sulfatide to evade lysosomal fusion** strongly suggests **Mycobacterium tuberculosis**, a bacterium for which rifampin is a cornerstone treatment.
*Pyrazinamide*
- **Pyrazinamide** is a prodrug that, once converted to **pyrazinoid acid**, disrupts **mycobacterial membrane potential** and metabolism. Its primary target is not RNA synthesis.
- Its efficacy is pH-dependent and it acts optimally in acidic environments, such as within macrophages, but mutations affecting RNA synthesis would not directly compromise its action.
*Ethambutol*
- **Ethambutol** inhibits **arabinosyl transferase**, an enzyme essential for the synthesis of the **mycobacterial cell wall component arabinogalactan**.
- Its mechanism of action is distinct from RNA synthesis, thus mutations affecting RNA polymerase would not impact its efficacy.
*Streptomycin*
- **Streptomycin** is an **aminoglycoside antibiotic** that binds to the **30S ribosomal subunit**, inhibiting bacterial **protein synthesis**.
- This mechanism is unrelated to DNA-dependent RNA polymerase, so mutations in RNA synthesis enzymes would not affect streptomycin's action.
*Levofloxacin*
- **Levofloxacin** is a **fluoroquinolone antibiotic** that inhibits **bacterial DNA gyrase (topoisomerase II)** and **topoisomerase IV**, thereby blocking DNA replication and transcription.
- While it affects processes related to DNA, its direct target is not the DNA-dependent RNA polymerase enzyme itself, distinguishing it from rifampin's specific mechanism.
Cost-effective antimicrobial strategies US Medical PG Question 9: A 15-year-old boy presents with his father to the urgent care with 5 days of frequent diarrhea, occasionally with streaks of blood mixed in. Stool cultures are pending, but preliminary stool samples demonstrate fecal leukocytes and erythrocytes. His vital signs are as follows: blood pressure is 126/83 mm Hg, heart rate is 97/min, and respiratory rate is 15/min. He is started on outpatient therapy for presumed Shigella infection. Which of the following is the most appropriate therapy?
- A. Oral doxycycline
- B. Oral vancomycin
- C. Oral TMP-SMX
- D. Oral azithromycin (Correct Answer)
- E. Oral ciprofloxacin
Cost-effective antimicrobial strategies Explanation: ***Oral azithromycin***
- **Azithromycin** is the **first-line empiric treatment** for suspected **Shigella infection** based on current CDC and WHO guidelines, particularly in pediatric and adolescent patients.
- The presence of **fecal leukocytes and erythrocytes** indicates an invasive bacterial infection, which warrants antibiotic therapy to shorten the course of illness and reduce transmission risks.
- Azithromycin has excellent efficacy against Shigella with relatively low resistance rates compared to older agents, and it is well-tolerated in adolescents.
*Oral TMP-SMX*
- **TMP-SMX (trimethoprim-sulfamethoxazole)** was historically first-line for Shigella, but **widespread resistance** (often >50% globally) has made it no longer recommended for empiric therapy.
- It may still be used if culture and susceptibility testing confirm sensitivity, but should not be chosen empirically.
*Oral ciprofloxacin*
- **Ciprofloxacin**, a fluoroquinolone, is highly effective against **Shigella** and is first-line in adults.
- However, its use in **pediatric patients under 18 years** is generally limited due to potential adverse effects on **cartilage development** and risk of tendinopathy.
- In a 15-year-old, while approaching adult age, azithromycin remains preferred unless there are specific contraindications.
*Oral doxycycline*
- **Doxycycline** has limited activity against **Shigella** and is not considered appropriate empiric therapy for this infection.
- It is more commonly used for atypical pathogens, certain sexually transmitted infections, or specific tick-borne diseases.
*Oral vancomycin*
- **Oral vancomycin** is primarily used to treat **Clostridioides difficile infection** (CDI) and is completely ineffective against **Shigella**.
- Vancomycin acts only on gram-positive bacteria and does not penetrate the systemic circulation when given orally, making it unsuitable for gram-negative enteric infections.
Cost-effective antimicrobial strategies US Medical PG Question 10: A 55-year-old woman presents to the physician because of a fever 4 days after discharge from the hospital following induction chemotherapy for acute myeloid leukemia (AML). She has no other complaints and feels well otherwise. Other than the recent diagnosis of AML, she has no history of a serious illness. The temperature is 38.8°C (101.8°F), the blood pressure is 110/65 mm Hg, the pulse is 82/min, and the respirations are 14/min. Examination of the catheter site, skin, head and neck, heart, lungs, abdomen, and perirectal area shows no abnormalities. The results of the laboratory studies show:
Hemoglobin 9 g/dL
Leukocyte count 800/mm3
Percent segmented neutrophils 40%
Platelet count 85,000/mm3
Which of the following is the most appropriate pharmacotherapy at this time?
- A. Valacyclovir
- B. Vancomycin
- C. Imipenem (Correct Answer)
- D. Caspofungin
- E. Ciprofloxacin
Cost-effective antimicrobial strategies Explanation: ***Imipenem***
- This patient presents with **febrile neutropenia** (fever >38.3°C and absolute neutrophil count <500/mm³ or expected to fall below 500/mm³). This is a **medical emergency** requiring prompt empiric **broad-spectrum antibiotic** therapy covering **Gram-positive** and **Gram-negative** organisms.
- **Imipenem** is a carbapenem antibiotic with broad-spectrum activity, making it an appropriate choice for empiric treatment of febrile neutropenia, especially in high-risk patients like those undergoing induction chemotherapy for AML.
*Valacyclovir*
- **Valacyclovir** is an antiviral medication used primarily for **herpes simplex** and **varicella-zoster virus** infections.
- While immunocompromised patients are susceptible to viral infections, there is no clinical evidence at this time to suggest a viral etiology, and **febrile neutropenia** takes precedence for immediate broad-spectrum antibacterial coverage.
*Vancomycin*
- **Vancomycin** is an antibiotic that specifically targets **Gram-positive bacteria**, particularly **methicillin-resistant Staphylococcus aureus (MRSA)**.
- Empiric vancomycin is not typically recommended as initial sole therapy for febrile neutropenia unless there is strong suspicion of a Gram-positive infection (e.g., catheter-related infection, mucositis, skin and soft tissue infection, or known colonization with MRSA), which is not present here.
*Caspofungin*
- **Caspofungin** is an **antifungal** medication used to treat invasive fungal infections, including candidiasis and aspergillosis.
- Initial management of febrile neutropenia focuses on bacterial infections; empiric antifungal therapy is usually initiated if fever persists despite broad-spectrum antibiotics for several days.
*Ciprofloxacin*
- **Ciprofloxacin** is a fluoroquinolone antibiotic with good activity against many **Gram-negative bacteria** but limited activity against **Gram-positive organisms** and anaerobes.
- While it can be used for prophylaxis or as part of a combination regimen, it is not considered sufficient as a single agent for empiric treatment of **high-risk febrile neutropenia** due to its limited spectrum and increasing resistance patterns.
More Cost-effective antimicrobial strategies US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
